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RCR cells are NRK clones in which Raf-1 production is blocked by the expression of an antisense RNA, and consequently they are refractory 
to transformation by various oncogenes. In RCR cells, MAP kinases (ERKl and ERK2) were activated to an extent and in a time course similar 
to those of the original NRK cells, irrespective of whether the stimulus was oncogenic or non-oncogenic. Moreover, there was no significant 
elevation of ERK activities in oncogene-transformed NRK cells. These results indicate that Raf-1 kinase is not the major upstream activator of 
ERK’s in NRK cells and that neither ERKl nor ERK2 are likely to mediate oncogenic signals from Raf-1 kinase. 
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1. INTRODUCTION 
Several distinct families of serine-threonine kinases 
constitute evolutionarily well-conserved signal path- 
ways involved in growth and differentiation control of 
a wide variety of eukaryotes from unicellular to mul- 
ticellular organisms. Among them are the mitogen-acti- 
vated protein kinases (also called extracellular signal- 
regulated kinases or ERK’s) and Raf-1 kinase. ERK’s, 
existing as at least two isoforms called ERKl (44 kDa) 
and ERK2 (42 kDa), are thought to play an important 
role in the regulation of the G,,/G, transition, meiosis 
and differentiation [l]. Raf-1 kinase (70-75 kDa), en- 
coded by the cellular homologue of the v-ruf oncogene 
[2], mediates growth and differentiation signals in mam- 
mals and flies [3]. 
ERK activation [16]. Thus, quantitatively and qualita- 
tively what role ERK’s play in signal transduction medi- 
ated by c-ruf-1 is highly controversial. 
We have been i vestigating cascades involved in on- 
cogenic signal transduction by employing NRK cell mu- 
tants [ 17 and NRK cell clones (RCR) blocked in Raf- 1 
kinase production by c-r&l antisense xpression [181. 
From the studies, we have concluded that the oncogenic 
signals originating from growth factors and a majority 
of oncogenes are transduced via a common pathway 
involving Raf-1 kinase as a key downstream mediator. 
These oncogenes include v-erbB, activated c-erbB-2, 
v-fms, v-rus, v-mos, v-src, SV40 T antigen, poliomavirus 
middle T antigen, human papillomavirus E6E7 and 
v-fos. This signal cascade is distinct from those for the 
regular anchorage-dependent mitogenic signals. 
Both ERK’s and Raf-1 kinase in quiescent fibroblasts 
are rapidly activated in response to a wide variety of 
growth stimuli such as epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), fibroblast 
growth factor, insulin, insulin-like growth factor I, and 
phorbol esters [4-lo]. In some cells, MAP kinases are 
constitutively activated following rus, v-ruf, or v-src 
transformation [l l-141. MAP kinase kinase (or MEK), 
a direct upstream regulator of ERK’s, undergoes activa- 
tion by Raf- 1 in vitro [ 12,151. Based on these data, it has 
been postulated that ERK’s mediate signals originating 
from Raf-1 and may play a role in the transduction of 
oncogenic signals and/or in the maintenance of trans- 
formation. However, continuous elevation of ERK ac- 
tivity was failed to be detected in rus- and v-ruf-trans- 
formed rat fibroblasts [14]. Moreover, a recent report 
with the baculovirus system suggests that Raf-l- 
dependent and independent pathways may exist for 
To clarify if Raf-1 is a major upstream activator of 
ERK’s in vivo and if ERK’s mediate oncogenic signals 
from Raf-1, we examined the activities of ERK’s in 
RCR cells and in NRK cells transformed by EGF plus 
transforming growth factor-/? (TGF-/3) or various onco- 
genes. Here we show that Raf-1 is not the main up- 
stream activator of ERKl and ERK2 and that neither 
of them is likely to mediate the oncogenic signals. 
2. MATERIALS AND METHODS 
2.1. Cells and chemicals 
*Corresponding author. Fax: (81) (75) 712-5492. 
The NRK-49F cell line was obtained from the American Type 
Culture Collection. RCR4 was established after transfection of NRK 
with the rcr(-) plasmid encoding an antisense sequence to the S-end 
of c-raf-1 [18]. v-erbB, v-fms, v-ras, v-fes, f-src, v-fos or v-raf-trans- 
formed NRK cells were prepared by DNA transfection following 
G418 selection [17,18]. All the cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMED) supplemented with 5% fetal calf 
serum, penicillin (100 U/ml) and streptomycin (100 mg/ml) in 5% CO2 
at 35°C. TGF-B, EGF and PDGF (culture grade) were purchased 
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from Nakarai Tesque Inc., Toyobo Inc. and R&D system, respec- 
tively. To stimulate growth, growth factors were added to the culture 
at final concentrations of 5 @ml for EGF, 5 r&ml for PDGF or 
1 ng/ml for TGF;B, unless indicated in the text. 
2.2. Preparation of cell lysates 
5 x lo5 cells were seeded into a 60 mm-dish and incubated overnight. 
Following serum starvation for 48 h, the cells were stimulated with 
each growth factor for the indicated time, washed with ice-cold PBS 
and scraped in 0.5 ml of an ice-cold lysis buffer (20 mM Tris-HCl, 
pH 7.5, 5 mM EGTA, 0.5% Triton X-100, 50 mM 2-glycerophosphate, 
1 mM phenylmethylsulfonyl fluoride, 2% aprotinin, 6 mM dithiothre- 
itol and 1 mM sodium orthovanadate) [4]. The collected cells were 
homogenized and centrifuged at 15,000 rpm for 30 min with a micro- 
centrifuge at 4°C. The supernatant was stored at -80°C until use. 
2.3. In-gel kinase assay 
For in-gel kinase assay [ 191, 5 pg of cell lysate was loaded on each 
lane and electrophoresed on a 9% SDS-polyacrylamide gel containing 
bovine brain myelin basic protein (Sigma) at a concentration of 
0.5 mg/ml as a substrate. The gel was treated with 6 M guanidine-HCl 
and with a 0.04% Tween-40-containing buffer at 4°C then incubated 
with 2.5 ,UZi [y-‘*P]ATP/ml and washed with 5% trichloroacetic acid/ 
1% pyrophosphate. The gel was dried and exposed to a X-ray film for 
1548 h at -80°C. 
2.4. Western blot analysis 
Western blot analysis was carried out as described previously [18]. 
Briefly, 10 pg and 7 ,ug of cell lysates were used for Raf-1 and ERK 
detection, respectively. The lysates were boiled for 3 min and electro- 
phoresed on 10% SDS-polyacrylamide gels and transferred to nitrocel- 
lulose filters. The filters were pretreated with TBST (20 mM Tris-HCl, 
pH 8.0, 150 mM NaCl, 0.05% Tween 20) containing 5% non-fat dry 
milk and 1% BSA, and then probed with the antiSP63 antibody that 
had been generated against the carboxyl-terminal 12 amino acids 
unique to Raf-1 [20] (prepared by Medical and Biological Laborato- 
ries Inc.) or the anti-ERKl serum [21] which recognizes two proteins 
with approximate molecular weight of 42 and 44 kDa corresponding 
to ERK2 and ERKl, respectively . 
3. RESULTS 
3.1. ERKactivation is not accompanied with transforma- 
tion 
Our previous studies have shown that the oncogenic 
signals originating from EGF plus TGF-/3 and a major- 
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Fig. 1. Time courses of ERK activation in NRK cells. After 48 h serum 
starvation, NRK cells were stimulated with 5% FCS, EGF, PDGF, 
or EGF plus TGF-/3. The lysis buffer was added to the culture at the 
time indicated in the figure. The lysates containing 5 pug protein were 
analyzed by in-gel kinase assay as described in section 2. 
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Fig. 2. (A) Morphologies of NRK cells transformed by growth factors 
and various oncogenes. NRK cells exponentially growing in growth 
medium, or exposed to EGF plus TGF-p for 48 h were indicated as 
none, or EGF + TGF-p. Transformants were generated by introduc- 
tion of the oncogenes indicated in the figure. (B) ERK activity in 
transformed NRK cells. The cells in Fig. 2A were lysed, and lysates 
containing 5 pg protein were subjected to in-gel kinase assay. 
ity of oncogenes are transduced through a common 
signal pathway and that Raf-1 is a downstream compo- 
nent of this pathway [17,18]. If ERK’s are indeed major 
downstream effecters of Raf-1 kinase as suggested by 
the in vitro studies and play a key role in the oncogenic 
signal transduction, there must be a strong correlation 
between the activation of ERK’s and the occurrence of 
transformation. We addressed this point by comparing 
the extent and time course of ERK activation in NRK 
cells following oncogenic or non-oncogenic growth 
stimulation. Growth-arrested NRK cells typically pro- 
gress into S phase within 6 h and Gz phase within 12 h, 
and return to G, by 20-22 h after growth stimulation 
(data not shown). Growth-arrested NRK cells were 
treated with serum, EGF or PDGF as a non-oncogenic 
stimulus or EGF plus TGF-/I as an oncogenic stimulus, 
and the time course and extent of ERK activation were 
determined by the in-gel kinase assay. In good agree- 
ment with the previous reports, both ERKl and ERK2 
were activated by serum and the growth factors within 
1 min after stimulation, peaked at 10 min and then fell 
gradually to the basal level (Figs. 1 and 4). The maxi- 
mum activation of ERK2 was 2-3 times the basal level. 
On the contrary, ERKl responded more clearly. The 
ERKl activity was almost undetectable in growth- 
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Fig. 3. After 48 h serum starvation, NRK and RCR cells were stimu- 
lated to grow with 5% FCS, EGF, PDGF, or EGF plus TGF;B for 
10 min. (A) Expression of Raf-I. The level of Raf-1 protein was 
examined by Western blot analysis as described in section 2. Lanes: 
(1) NRK with no stimulation; (2) RCR4 with no stimulation; (3) 
RCR4 with FCS; (4) RCR4 with EGF; (5) RCR with PDGF; (6) 
RCR4 with EGF plus TGF-B. (B) Expression of ERK’s. The levels 
of ERKl and ERK2 proteins were determined by Western blot anal- 
ysis. Lanes: (1) NRK with no stimulation; (2) RCR4 with no stimula- 
tion; (3) NRK with FCS; (4) RCR4 with FCS; (5) NRK with EGF; 
(6) RCR4 with EGF; (7) NRK with PDGF; (8) RCR4 with PDGF; 
(9) NRK with EGF plus TGF;B; (10) RCR4 with EGF plus TGF-/?. 
arrested cells, elevated to a level comparable to that of 
ERK2, and then fell to an undetectable level within 2 h. 
Upon treatment with EGF plus TGF-/3, NRK cells un- 
derwent transformation within 48 h (Fig. 2A). How- 
ever, the time course and the extents of the activation 
of ERKl and ERK2 by the oncogenic stimulus were 
similar to those by non-oncogenic stimuli, suggesting 
that there is no particular association of ERK activa- 
tion with the transformation process. 
3.2. ERK activity is not elevated in transformed NRK 
cells 
The lack of the association of ERK activation with 
transformation was also observed in fully transformed 
NRK cells. Cell lysates were prepared from NRK cells 
transformed by EGF plus TGF-/3, v-e&B, v-fms, V-KC 
ras, v-src, v-fes, v-fos or v-raf (Fig. 2A), and their ERK 
activities were determined by the in-gel kinase assay. As 
shown in Fig. 2B, the ERK2 activity was detectable but 
not significantly different between the fully transformed 
and untransformed cells. On the other hand, the ERKl 
activity was undetectable in both types of cells. Strik- 
ingly, neither ERKl nor ERK2 was activated in v-raf- 
transformed cells. The activation of ERKl and ERK2 
by non-oncogenic as well as oncogenic growth stimuli 
and no significant elevation of the ERK activity in the 
fully transformed, particularly v-raf-transformed, cells 
indicate that Raf-1 kinase is not the major activator of 
ERKl and ERK2 and that ERKl and ERK2 are un- 
likely to mediate oncogenic signals originating from 
growth factors and oncogenes. 
3.3. ERK activity is not inJuenced by the presence or 
absence of Raf-I kinase 
To obtain further evidence, the ERKl and ERK2 
activities in RCR cells that was blocked in Raf-1 pro- 
duction were assayed following stimulation with serum, 
EGF, PDGF or EGF plus TGF-/I. 
The levels of the Raf-1, ERKl and ERK2 proteins 
during the stimulation were unchanged in NRK and 
RCR cells, as verified by Western blotting with specific 
antibodies that detected Raf-1 or ERKl and ERK2 
[20,21]. No Raf-1 band was detectable in RCR4 cells, 
irrespective of the presence or absence of growth stimu- 
lation with serum, EGF, PDGF or EGF plus TGF-/I 
(Fig. 3A). The levels of ERKl and ERK2 were not 
influenced either (Fig. 3B). 
RCR4 cells were stimulated with serum, EGF, PDGF 
or EGF plus TGF-B for 1 to 30 min, and assayed for 
ERK activity (Fig. 4). ERKl and ERK2 in the RCR 
cells were activated with a time course and to a extent 
both very similar, if not identical, to those in NRK cells. 
Virtually identical results were obtained with other 
RCR cells (RCRl, -2, -3, -5, -6) (data not shown). Thus, 
in NRK cells, ERKl and ERK2 were activated to the 
same extent and with the same time course, irrespective 
of whether the stimuli were oncogenic or non-onco- 
genie, and their activation was unchanged with or with- 
out Raf-1 kinase. From these results, we conclude that 
in NRK cells Raf-1 is not the main upstream regulator 
of ERKl and ERK2 and that neither ERKl nor ERK2 
is likely to mediate the oncogenic signal. 
4. DISCUSSION 
We have shown that in rat fibroblasts Raf-1 kinase 
is not the main upstream activator of ERKl and ERK2 
and that neither ERKl nor ERK2 is likely to be a down- 
stream mediator of the oncogenic signal from Raf-1. 
Our results do not support, if not contradict, the recent 
in vitro biochemical data and the functional data in 
NRK RCR4 
min 0 15103060015103060 
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Fig. 4. ERK activity in RCR4 cells after growth factor stimulation. 
After 48 h serum starvation, NRK and RCR4 cells were stimulated 
with 5% FCS, EGF, PDGF, or EGF plus TGF-p. The lysis buffer was 
added to the culture at the time indicated in the figure. The lysates 
containing 5 pug protein were subjected to in-gel kinase assay. 
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yeast, both indicating that mammalian Raf-I kinase is 
capable of activating MAP kinase kinase (MEK) and, 
consequently, ERK’s [ 12,15,22]. In general, biochemi- 
cal reactions seen with partially purified enzymes and 
functional interactions obtained under overexpression 
in yeast often magnify events that only rarely occur 
under physiological conditions. This may be the case for 
ERK activation by Raf-1. 
If Raf-1 were not the major activator of ERK’s in 
vivo, then what would the activator be? In yeast, protein 
kinases homologous to ERK’s and MEKl constitute 
signal cascades for the regulation of pheromone- 
induced sexual development and growth-associated 
budding [23]. In budding yeast STE7 and FUS3 consti- 
tute the pheromone signal cascade whereas MKKl/ 
MKK2 and MPKl constitute a cascade for the regula- 
tion of osmosis during budding. STE7 and MKKlI 
MKK2 are highly homologous not only mutually but 
also with MEKl of mammals. Similarly, FUS3 and 
MPKl are highly homologous not only mutually but 
also with ERKl/ERK2 of mammals. In these cascades, 
STE7 and MKKl/MKK2 are regulated by STEll and 
BCKl, respectively. STEll and BCKl are mutually 
homologous but not with Raf-1 kinase. Thus, in these 
signal cascades, the MAP kinase kinase family is regu- 
lated by another kinase family dissimilar to Raf- 1. Re- 
cently a kinase similar to STEll has been identified in 
mice as an activator of MEKl [24]. These data taken 
together with ours suggest that in close similarity to the 
yeast cascades, MEKl may mainly be regulated by a 
STEl l-like kinase(s). 
It has been reported that the ERK activity is constitu- 
tively elevated in rus- and ruf-transformed NIH 3T3 or 
Swiss 3T3 cells and in g@2- and src-transformed Rat 1 a 
fibroblasts, but not in rus- and raf-transformed Rat la 
cells [l 1,12,13,25]. We failed to observe an elevation 
of the ERK activity in transformed, even v-raf-trans- 
formed, rat NRK cells. Such inconsistency supports our 
conclusion that ERK’s do not play a crucial role in 
oncogenic signal transduction. The reason for the acti- 
vation of ERK’s in certain cell types by certain onco- 
genes is unclear but could be subtle differences in some 
phosphorylation dephosphorylation metabolism brought 
about by transformation. 
Finally, what would the immediate downstream me- 
diator of oncogenic signals from Raf-1 kinase be? In 
flies, a signal cascade comprised of a PDGF receptor- 
like receptor called torso and D-raf kinase plays a cen- 
tral role in growth and differentiation regulation [26]. 
Recently a gene (&ml) encoding a MEKl-like kinase 
has been identified as an extragenic suppresser of a 
Raf-1 kinase mutant fly [27]. In light of our data, this 
finding suggests that a downstream effector of Raf-1 
kinase might not be MEKl but a kinase similar to 
MEKl. We and others recently identified MEK2, a 
MEKl homologue, from rat and mouse [28,29]. This 
might be a candidate for a Raf-1 effector. 
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